Abstract: Starting materials of phosphasugars, 1-phenyl-2-phospholene 1-oxides, were prepared from dienes and phenylphosphonous dichloride (dichlorophenylphosphine). Several substituted novel phosphasugars (3-or 4-halo-substituted)-1-phenyl-2-phospholene 1-oxides as well as 1-phenyl-2-phospholane 1-oxides were prepared from 2-phospholenes. The synthesized compounds were evaluated for their antitumor activities against the leukemia cell lines (U937 and K562) by in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 2,3,4-Tribromo-3-methyl-1-phenylphospholane 1-oxide showed superior antitumor activity against U937 and K562 cell lines in a comparative evaluation with Glivec. The analysis by flow cytometry implied that 2,3-dibromo-3-methyl-1-phenylphospholane 1-oxide induced apoptosis to leukemia cell lines.
INTRODUCTION
Phosphorus compounds and sugar derivatives are deeply related to birth, growth, sustenance, reproduction, death, etc., of living things. The replacement of an oxygen-phosphorus bond of a phosphonate affords a carbon-phosphorus bond of a phosphonate, which bestows phosphonates on hydrolytically stable phosphorus derivatives to their phosphate analogues, and the mode of action of phosphonates is often brought by either competitive interaction with the substrate binding regions or as an analogue of the tetrahedral transition states. As a result, synthetic phosphonates were found to be applicable to medicines or agricultural medicines of antibiotics, antivirals, antiosteoclastics, and environmentally friendly herbicides [1] . The phosphonate moiety of the derivatives is also well represented in biologically active
RESULTS AND DISCUSSION

Synthesis
A series of branched phosphasugar analogues of 1-phenyl-2-phospholene 1-oxides 2a-c; 4-halo-1-phenyl-2-phospholene 1-oxides 3b,c, 7, and 8; 2,3-dibromo-1-phenyl-2-phospholane 1-oxides 4b,c; 2,3-epoxy-3-methyl-1-phenylphospholane 1-oxide 5; 2,3,4-tribromo-3-methyl-1-phenylphospholane 1-oxide (6); and 1-(3-substituted phenyl)-2-phospholene 1-oxides 9-12 as described in Schemes 1-4 were prepared. While the synthesis of compounds 2a-c was previously described [16] , we report herein the more simplified and efficient synthetic methods to produce these compounds. Compounds 1a-c were prepared from dienes and phenylphosphonous dichloride (phenyldichlorophosphine) by McComack reaction (Scheme 1). Compounds 3b,c were prepared from compounds 2b,c and N-bromosuccinimide (NBS) by substitution reaction of the hydrogen on the 4-position by a bromo radical in the presence of 2,2'-azobisisobutyronitrile (AIBN) catalyst (Scheme 2). Compounds 4b,c and 6 were prepared from compounds 2b,c and 3b, respectively, by addition reaction of bromine in the presence of catalyst (Schemes 2 and 3). 2,3-Anhydrophosphasugar 5 was prepared by epoxidation of 2b with m-chloroperbenzoic acid (mCPBA). 4-Deoxyhalophosphasugars 7 and 8 were prepared from 2b and 3b, respectively, by substitution reactions with chloro-radical and iodonium anion, respectively. 1-(3-Substituted phenyl)phosphasugars 9 and 10 were prepared from compound 2b by nitration with HNO 3 /H 2 SO 4 and successive treatment with SnCl 2 and HCl. And then, compounds 11 and 12 were prepared by the same process as monobromides 3b,c preparation. The structures of the phosphasugar derivatives were determined by analytical and spectroscopic measurements.
sugars have isomers, which were subjected to the isolation and the in vitro evaluation, otherwise, isomer separation is not mentioned. The results are summarized in Tables 1 and 2 . As shown in Table 1 , the proliferation of K562 and U937 cells were inhibited by compounds 3b,c and 11. Results showed that antileukemia activities for compounds 3b,c were 87.3 and 18.5 μmol/l (μM) with regard to 50 % cell growth inhibition (IC 50 ) value against K562 cells. Besides, Tables 1 and 2 show that the effects of compounds 3b,c and 11 on the inhibition of cell proliferation (IC 50 ) were 83.3, 5.9, and 19.8 μM, respectively, against U937 cells. On the other hand, compounds 2a-c, 7-9, 10, and 12 did not inhibit the leukemia cells. The results suggested that dehydrophosphasugars 3b,c, 11, and 12 substituted by bromo group have higher activity against K562 and U937 cells than the other derivatives 2a-c and 7-10. Substituents of chloro and iodo groups have less antileukemia activity than the bromo group for the inhibition. Therefore, dibromides 4b,c and tribromide 6 were synthesized and evaluated against the leukemia cells. Table 2 shows that the substituents of bromo or epoxy groups have high antitumor activity against K562 and U937. Interestingly, the antileukemia activities depended on the number of bromo substituents introduced into the phosphasugar molecules. Furthermore, the results showed that the deoxybromophosphasugars have remarkably high antileukemia activity against both K562 and U937 cells. On the contrary, Imatinib mesylate has no or less effect against U937 cells viability (IC 50 > 500 μM). The methyl and/or bromo substituent effects of 2-phospholenes and phospholanes at C3 and C4 positions and/or C2, C3, and C4 positions, suggest that they are important substituents on the antiproliferative effects. The results imply that the phosphasugars with the larger number of those substituents should fulfill the excellent antileukemia activity. Diastereoisomer Some deoxybromophosphasugars such as dibromide 4 include diastereoisomers. Dibromides 4 have four diastereoisomers 4ba-bd because the stereoselectivity of the addition reaction of bromine to the C=C double bond of the C2 and C3 positions of 2-phospholene derivatives was partially controlled by the substituents on the chiral center of the phenyl and phosphoryl groups. The structures of the diastereomers are shown in Table 3 . In particular, 1 H NMR spectra of compounds 4b, which have four isomers 4ba-bd, showed different proton chemical shifts of H and Me groups on the C2 and C3 positions of the phosphorus heterocycles, and then each structure of the diastereomers is assigned to 4ba-bd whose retention time for each isomer consists with the polarity and the structure (Table 3) , and the 1 H NMR spectrum data also supports the structures of the diastereomers. The activities of these dibromo substituted phosphasugars 4ba-bd were also evaluated by MTT in vitro method for antitumor agents against human leukemia K562 and U937 cell lines (Table 3) . M. YAMAOKA et al.
Among the four diastereomers 4ba-bd, (2S,3R)-dibromo-(3R)-methyl-(1S)-phenylphospholane (1S)-oxide and the enantiomer, 1,2-erythro-2,3-cis-dibromo-3-methylphospholane 1-oxide and its enantio mer 4bd had the largest retention time and the largest dipole moment, and its antileukemia activity against K562 and U937 cells was highest (the values of IC 50 were 29 and 20 μM, respectively). The order of the antileukemia activities was 1,2-erythro-2,3-cis 4bd > 1,2-threo-2,3-cis 4ba > 1,2-erythro-2,3-trans 4bb > 1,2-threo-2,3-trans 4bc, depending on the structure of the diastereomers.
Flow cytometry
Cell cycle analysis for dibromide 4b was carried out by flow cytometry, and the results are shown in Fig. 1 . The distributions (%)
CONCLUSION
Phosphasugar analogues were synthesized and evaluated by in vitro MTT methods. Dehydrobromophosphasugars 3, 4, 6, and 11 caused growth inhibition of cells against leukemia cell lines of K562 and U937. Among them, compound 6 may most plausibly be a novel antitumor agent or drug which acts on the gene at the new mitosis stage to induce apoptosis by controlling the mitosis at the lower concentration. By the further research on phosphasugars or phosphorus heterocycles, it may be more plausible that the present medicinal chemistry will lead to novel and wide spectral molecular targeted chemotherapeutic drugs for human cancers. Further research on these phosphasugars or phosphorus heterocycles and their bioactivities is now under development. Preparation of 2-phospholenes 2 Synthesis of 3,4-dimethyl-1-phenyl-2-phospholene 1-oxide (2c): 2,3-Dimethyl-1,3-butadiene 10 ml (90 mmol; 1.0 equiv) and phenylphosphonous dichloride 16 ml (120 mmol; 1.30 equiv) were mixed and reacted at room temperature for 2 weeks. The formed solid 3,4-dimethyl-1-phenyl-2-phospholenium dichloride was dissolved in chloroform (200 ml) and hydrolized at 0 °C by addition of ice. The reaction mixture was neutralized with sodium hydrogencarbonate and then filtered and extracted with chloro form (20 ml × 3). The chloroform extract was washed with water (50 ml), saturated sodium hydrogencarbonate solution (50 ml), and saturated sodium chloride solution (50 ml). Drying over the chloroform extract with anhydrous sodium sulfate followed by filtration, evaporation of the solvent in vacuo, and distillation under the reduced pressure afforded 3,4-dimethyl-1-phenyl-2-phospholene 1-oxide (2c; 5. 
Preparation of 4-bromo-2-phospholenes 3
Synthesis of 4-bromo-3,4-dimethyl-1-phenyl-2-phospholene 1-oxide (3c): To a chloroform (3 ml) solution of 3,4-dimethyl-1-phenyl-2-phospholene 1-oxide (2c; 206.1 mg, 1.00 mmol, 1.0 equiv) and NBS (213.6 mg, 1.20 mmol, 1.2 equiv) was added dropwise a chloroform (3 ml) solution of 2,2'-azobisisobutyronitrile (AIBN; 24.6 mg, 0.15 mmol, 0.15 equiv) at 60 °C and the reaction mixture was refluxed for 6 h under Ar atmosphere. The reaction mixture was neutralized with saturated NaHCO 3 aqueous solution (10 ml), washed with water (10 ml) and saturated NaCl solution (10 ml), and dried over anhydrous sodium sulfate. The solvent of the filtrate was evaporated under a reduced pressure to give an oily residual material. The residue was purified by column chromatography on silica gel by using chloroform and methanol (20:1) as the eluent to give 4-bromo-3,4-dimethyl-1-phenyl-2- 
Preparation of 2,3-dibromophospholanes 4
Synthesis of 2,3-dibromo-3,4-dimethyl-1-phenylphospholane 1-oxide (4c): 2-Phospholene 1-oxide 2c (0.206 g, 1.00 mmol) was dissolved in CH 2 Cl 2 (5 ml). MnO 2 (0.24 g, 2.4 mmol) was added to the solution and then slow addition of CH 2 Cl 2 solution of bromine (0.50 ml) was followed. The reaction mixture was stirred for 8 h at room temperature, and then the mixture was diluted with CH 2 Cl 2 and vacuum filtered. The filtrate was collected, washed with 10 % Na 2 SO 3 solution, water, and brine, and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent followed by purification through silica gel column with chloroform and methanol (20:1) provided 2,3-dibromo-3,4-dimethyl-1- Similarly, 4b was prepared.
M. YAMAOKA et al. Preparation of 2,3-epoxyphospholane 5 Synthesis of 2,3-epoxy-1-phenylphospholane 1-oxide (5): To a stirred mixture of 1-phenyl-2-phospholene 1-oxide (2b; 0.384 g, 2.00 mmol) in CHCl 3 (5 ml) was added mCPBA (0.587 g, 3.40 mmol), and then stirred for additional 24 h at 60 °C. The reaction mixture was neutralized with saturated NaHCO 3 aqueous solution (10 ml), washed with water (10 ml) and saturated NaCl solution (10 ml), and dried over anhydrous sodium sulfate. The solvent of the filtrate was evaporated under a reduced pressure to give an oily residual material. The residue was purified by column chromatography on silica gel by using chloroform and methanol (20:1) as the eluent to give product 2,3-epoxy-1- Preparation of 4-chloro-2-phospholene 7 Synthesis of 4-chloro-3-methyl-1-phenyl-2-phospholene 1-oxide (7): Under Ar atmosphere, 3-methyl-1-phenyl-2-phospholene 1-oxide (2b; 0.178 g 1.0 mmol) was dissolved in chloroform (CHCl 3 ; 3.0 ml), N-chlorosuccinimide (NCS; 0.159 g 1.20 mmol) and AIBN (0.024 g, 0.15 mmol) were added to the reaction media. After stirring at 50 °C for 6 h, the reaction was cooled, diluted with CHCl 3 , and vacuum filtered. The filterate was collected, washed by saturated sodium hydrogencarbonate solution, water, and brine, and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent followed by purification through silica gel column with Preparation of 4-iodo-2-phospholene 8 Synthesis of 4-iodo-3-methyl-1-phenyl-2-phospholene 1-oxide (8): To 4-bromo-3-methyl-1-phenyl-2-phospholane 1-oxide (3b; 1.05 g, 3.9 mmol) in acetone solution (10.0 ml) was added sodium iodide (NaI; 1.2 g, 7.8 mmol). After stirring the reaction mixture at 35 °C for 6 h to complete the reaction, the reaction mixture was cooled, added sodium hydrogensulfite solution, diluted with CHCl 3 , and vacuum filtered. The filtrate was collected, washed with saturated sodium hydrogencarbonate solution, water, and brine, and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent followed by purification through silica gel column with chloroform and methanol 
